Payment overview · 2025
General Payments
$272.06
18 reported records · 7 companies
Healthcare provider profile · identity verified
Oscar Rodriguez, M.D.
Allopathic & Osteopathic Physicians|Internal Medicine · MAMOU, LA · NPI 1619983780
Verified facts
What the public records show
CMS Open Payments records show Oscar Rodriguez, M.D. received $272.06 in general payments during 2025 across 18 reported records.
Amgen Inc. accounted for 58.5% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 10 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Farxiga, Trelegy Ellipta, Trulance.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported CREON as an associated drug or biological on 91561 records involving 20616 distinct recipient NPIs. Public Medicare Part D data also shows 34 claims for Creon by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported LINZESS as an associated drug or biological on 87954 records involving 21815 distinct recipient NPIs. Public Medicare Part D data also shows 170 claims for Linzess by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYNTHROID as an associated drug or biological on 10655 records involving 4881 distinct recipient NPIs. Public Medicare Part D data also shows 75 claims for Synthroid by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported VRAYLAR as an associated drug or biological on 377741 records involving 62704 distinct recipient NPIs. Public Medicare Part D data also shows 58 claims for Vraylar by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported FARXIGA as an associated drug or biological on 106133 records involving 42906 distinct recipient NPIs. Public Medicare Part D data also shows 52 claims for Farxiga by this doctor in 2024.
GlaxoSmithKline, LLC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRELEGY ELLIPTA as an associated drug or biological on 131532 records involving 37148 distinct recipient NPIs. Public Medicare Part D data also shows 41 claims for Trelegy Ellipta by this doctor in 2024.
Salix Pharmaceuticals, a division of Bausch Health US, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRULANCE as an associated drug or biological on 2652 records involving 1501 distinct recipient NPIs. Public Medicare Part D data also shows 13 claims for Trulance by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| Amgen Inc. | Unresolved — no canonical attribution shown | $159.23 | 58.5% | 12 | 2025 |
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $25.23 | 9.3% | 1 | 2025 |
| GlaxoSmithKline, LLC. | Unresolved — no canonical attribution shown | $21.24 | 7.8% | 1 | 2025 |
| Salix Pharmaceuticals, a division of Bausch Health US, LLC | Unresolved — no canonical attribution shown | $17.48 | 6.4% | 1 | 2025 |
| Vanda Pharmaceuticals Inc. | Unresolved — no canonical attribution shown | $17.20 | 6.3% | 1 | 2025 |
| KYOWA KIRIN, INC. | Unresolved — no canonical attribution shown | $15.98 | 5.9% | 1 | 2025 |
| ABBVIE INC. | Unresolved — no canonical attribution shown | $15.70 | 5.8% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $272.06 | 18 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| OTEZLA Normalized: otezla |
Drug | Amgen Inc. | $87.84 | 5 | 2025 |
Source payment records
|
|||||
| REPATHA Normalized: repatha |
Biological | Amgen Inc. | $78.84 | 7 | 2025 |
Source payment records
|
|||||
| EVENITY Normalized: evenity |
Biological | Amgen Inc. | $27.99 | 4 | 2025 |
Source payment records
|
|||||
| FARXIGA Normalized: farxiga |
Drug | AstraZeneca Pharmaceuticals LP | $25.23 | 1 | 2025 |
Source payment records
|
|||||
| TRELEGY ELLIPTA Normalized: trelegy ellipta |
Drug | GlaxoSmithKline, LLC. | $21.24 | 1 | 2025 |
Source payment records
|
|||||
| RELISTOR Normalized: relistor |
Drug | Salix Pharmaceuticals, a division of Bausch Health US, LLC | $17.48 | 1 | 2025 |
Source payment records
|
|||||
| TRULANCE Normalized: trulance |
Drug | Salix Pharmaceuticals, a division of Bausch Health US, LLC | $17.48 | 1 | 2025 |
Source payment records
|
|||||
| FANAPT Normalized: fanapt |
Drug | Vanda Pharmaceuticals Inc. | $17.20 | 1 | 2025 |
Source payment records
|
|||||
| CRYSVITA Normalized: crysvita |
Drug | KYOWA KIRIN, INC. | $15.98 | 1 | 2025 |
Source payment records
|
|||||
| PROLIA Normalized: prolia |
Biological | Amgen Inc. | $6.88 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| FARXIGA farxiga |
2025 | Farxiga | 2024 | 52 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| TRELEGY ELLIPTA trelegy ellipta |
2025 | Trelegy Ellipta | 2024 | 41 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| TRULANCE trulance |
2025 | Trulance | 2024 | 13 Beneficiary count suppressed |
exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | CREON open payments reported associated product |
CMS Open Payments — General Payments 91561 supporting records · 20616 recipient NPIs · example record 1201352608 |
Creon · 2024 Exact normalized brand match · 1 Part D row |
34 | suppressed by CMS |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | LINZESS open payments reported associated product |
CMS Open Payments — General Payments 87954 supporting records · 21815 recipient NPIs · example record 1201352608 |
Linzess · 2024 Exact normalized brand match · 1 Part D row |
170 | 28 |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | SYNTHROID open payments reported associated product |
CMS Open Payments — General Payments 10655 supporting records · 4881 recipient NPIs · example record 1201352636 |
Synthroid · 2024 Exact normalized brand match · 1 Part D row |
75 | suppressed by CMS |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | VRAYLAR open payments reported associated product |
CMS Open Payments — General Payments 377741 supporting records · 62704 recipient NPIs · example record 1201352550 |
Vraylar · 2024 Exact normalized brand match · 1 Part D row |
58 | suppressed by CMS |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | FARXIGA open payments reported associated product |
CMS Open Payments — General Payments 106133 supporting records · 42906 recipient NPIs · example record 1206131362 |
Farxiga · 2024 Exact normalized brand match · 1 Part D row |
52 | suppressed by CMS |
| GlaxoSmithKline, LLC. Exact reporting entity; no affiliate inference |
2025 | TRELEGY ELLIPTA open payments reported associated product |
CMS Open Payments — General Payments 131532 supporting records · 37148 recipient NPIs · example record 1190332369 |
Trelegy Ellipta · 2024 Exact normalized brand match · 1 Part D row |
41 | suppressed by CMS |
| Salix Pharmaceuticals, a division of Bausch Health US, LLC Exact reporting entity; no affiliate inference |
2025 | TRULANCE open payments reported associated product |
CMS Open Payments — General Payments 2652 supporting records · 1501 recipient NPIs · example record 1231775445 |
Trulance · 2024 Exact normalized brand match · 1 Part D row |
13 | suppressed by CMS |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Amlodipine Besylate | Amlodipine Besylate | 757 | 118 |
| Levocetirizine Dihydrochloride | Levocetirizine Dihydrochloride | 566 | 94 |
| Gabapentin | Gabapentin | 544 | 84 |
| Levothyroxine Sodium | Levothyroxine Sodium | 543 | 71 |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 504 | 55 |
| Pantoprazole Sodium | Pantoprazole Sodium | 483 | 75 |
| Potassium Chloride | Potassium Chloride | 467 | 72 |
| Losartan Potassium | Losartan Potassium | 443 | 71 |
| Atorvastatin Calcium | Atorvastatin Calcium | 424 | 65 |
| Omeprazole | Omeprazole | 381 | 59 |
| Tramadol Hcl | Tramadol Hcl | 361 | 50 |
| Montelukast Sodium | Montelukast Sodium | 343 | 53 |
| Metformin Hcl | Metformin Hcl | 321 | 50 |
| Ezetimibe | Ezetimibe | 312 | 49 |
| Furosemide | Furosemide | 285 | 53 |
| Escitalopram Oxalate | Escitalopram Oxalate | 270 | 39 |
| Tizanidine Hcl | Tizanidine Hcl | 269 | 58 |
| Metoprolol Succinate | Metoprolol Succinate | 268 | 42 |
| Carvedilol | Carvedilol | 260 | 36 |
| Lisinopril | Lisinopril | 237 | 43 |
| Hydrochlorothiazide | Hydrochlorothiazide | 220 | 40 |
| Eliquis | Apixaban | 217 | 28 |
| Fluticasone Propionate | Fluticasone Propionate | 207 | 51 |
| Zolpidem Tartrate | Zolpidem Tartrate | 194 | 23 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 189 | 29 |
| Bupropion Hcl Sr | Bupropion Hcl | 180 | 26 |
| Nabumetone | Nabumetone | 178 | 34 |
| Clopidogrel | Clopidogrel Bisulfate | 176 | 29 |
| Tamsulosin Hcl | Tamsulosin Hcl | 173 | 28 |
| Quetiapine Fumarate | Quetiapine Fumarate | 171 | 21 |
| Linzess | Linaclotide | 170 | 28 |
| Spironolactone | Spironolactone | 156 | 28 |
| Buspirone Hcl | Buspirone Hcl | 153 | 28 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 145 | 31 |
| Promethazine Hcl | Promethazine Hcl | 141 | 30 |
| Azithromycin | Azithromycin | 134 | 79 |
| Alprazolam | Alprazolam | 126 | 16 |
| Simvastatin | Simvastatin | 123 | 20 |
| Trazodone Hcl | Trazodone Hcl | 121 | 19 |
| Sucralfate | Sucralfate | 119 | 22 |
| Meloxicam | Meloxicam | 117 | 16 |
| Warfarin Sodium | Warfarin Sodium | 115 | suppressed |
| Ondansetron Odt | Ondansetron | 112 | 24 |
| Repatha Sureclick | Evolocumab | 111 | 13 |
| Sertraline Hcl | Sertraline Hcl | 111 | 20 |
| Torsemide | Torsemide | 111 | 17 |
| Allopurinol | Allopurinol | 108 | 16 |
| Duloxetine Hcl | Duloxetine Hcl | 107 | 14 |
| Entresto | Sacubitril/Valsartan | 107 | 15 |
| Ozempic | Semaglutide | 107 | 20 |
| Diclofenac Sodium | Diclofenac Sodium | 101 | 25 |
| Famotidine | Famotidine | 96 | 19 |
| Movantik | Naloxegol Oxalate | 96 | 11 |
| Oxycodone-Acetaminophen | Oxycodone Hcl/Acetaminophen | 96 | 16 |
| Sulfasalazine | Sulfasalazine | 95 | 15 |
| Metoprolol Tartrate | Metoprolol Tartrate | 92 | 15 |
| Prednisone | Prednisone | 91 | 30 |
| Pramipexole Dihydrochloride | Pramipexole Di-Hcl | 89 | suppressed |
| Nebivolol Hcl | Nebivolol Hcl | 85 | 15 |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 82 | 11 |
| Fluoxetine Hcl | Fluoxetine Hcl | 80 | 12 |
| Trulicity | Dulaglutide | 80 | 12 |
| Oxycodone Hcl | Oxycodone Hcl | 79 | suppressed |
| Hydroxyzine Pamoate | Hydroxyzine Pamoate | 75 | 12 |
| Synthroid | Levothyroxine Sodium | 75 | suppressed |
| Nifedipine Er | Nifedipine | 74 | 12 |
| Pravastatin Sodium | Pravastatin Sodium | 73 | 14 |
| Pregabalin | Pregabalin | 72 | 13 |
| Baclofen | Baclofen | 71 | suppressed |
| Eszopiclone | Eszopiclone | 67 | 16 |
| Ropinirole Hcl | Ropinirole Hcl | 64 | 11 |
| Levofloxacin | Levofloxacin | 63 | 41 |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 62 | suppressed |
| Atenolol | Atenolol | 61 | suppressed |
| Glimepiride | Glimepiride | 61 | 11 |
| Lorazepam | Lorazepam | 61 | suppressed |
| Clonazepam | Clonazepam | 58 | suppressed |
| Meclizine Hcl | Meclizine Hcl | 58 | 13 |
| Morphine Sulfate Er | Morphine Sulfate | 58 | suppressed |
| Vraylar | Cariprazine Hcl | 58 | suppressed |
| Alfuzosin Hcl Er | Alfuzosin Hcl | 56 | suppressed |
| Mupirocin | Mupirocin | 56 | 30 |
| Digoxin | Digoxin | 54 | suppressed |
| Valsartan | Valsartan | 54 | 12 |
| Donepezil Hcl | Donepezil Hcl | 53 | suppressed |
| Hydroxychloroquine Sulfate | Hydroxychloroquine Sulfate | 53 | 11 |
| Metoclopramide Hcl | Metoclopramide Hcl | 53 | suppressed |
| Mounjaro | Tirzepatide | 53 | 11 |
| Farxiga | Dapagliflozin Propanediol | 52 | suppressed |
| Hydralazine Hcl | Hydralazine Hcl | 48 | suppressed |
| Jardiance | Empagliflozin | 48 | suppressed |
| Estradiol | Estradiol | 43 | suppressed |
| Mirtazapine | Mirtazapine | 43 | suppressed |
| Amoxicillin | Amoxicillin | 42 | 21 |
| Ibuprofen | Ibuprofen | 42 | suppressed |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 41 | suppressed |
| Xarelto | Rivaroxaban | 41 | suppressed |
| Memantine Hcl | Memantine Hcl | 40 | suppressed |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 39 | suppressed |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 39 | 30 |
| Divalproex Sodium | Divalproex Sodium | 37 | suppressed |
| Lansoprazole | Lansoprazole | 37 | suppressed |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 37 | suppressed |
| Clonidine Hcl | Clonidine Hcl | 36 | suppressed |
| Solifenacin Succinate | Solifenacin Succinate | 36 | suppressed |
| Benazepril Hcl | Benazepril Hcl | 35 | suppressed |
| Creon | Lipase/Protease/Amylase | 34 | suppressed |
| Fenofibrate | Fenofibrate Nanocrystallized | 34 | suppressed |
| Januvia | Sitagliptin Phosphate | 34 | suppressed |
| Nystatin | Nystatin | 34 | 15 |
| Sulfasalazine Dr | Sulfasalazine | 34 | suppressed |
| Tresiba Flextouch U-100 | Insulin Degludec | 34 | suppressed |
| Budesonide Dr | Budesonide | 33 | suppressed |
| Fluconazole | Fluconazole | 33 | 17 |
| Methylprednisolone | Methylprednisolone | 33 | 24 |
| Nitrofurantoin | Nitrofurantoin Macrocrystal | 33 | suppressed |
| Acetaminophen-Codeine | Acetaminophen With Codeine | 32 | suppressed |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 32 | suppressed |
| Propranolol Hcl | Propranolol Hcl | 31 | suppressed |
| Trintellix | Vortioxetine Hydrobromide | 31 | suppressed |
| Trimethoprim | Trimethoprim | 30 | suppressed |
| Humalog | Insulin Lispro | 29 | suppressed |
| Latanoprost | Latanoprost | 29 | suppressed |
| Bupropion Xl | Bupropion Hcl | 28 | suppressed |
| Citalopram Hbr | Citalopram Hydrobromide | 28 | suppressed |
| Sumatriptan Succinate | Sumatriptan Succinate | 28 | suppressed |
| Diazepam | Diazepam | 27 | suppressed |
| Irbesartan | Irbesartan | 27 | suppressed |
| Ultra-Fine Short Pen Needle | Pen Needle, Diabetic | 27 | suppressed |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 26 | suppressed |
| Fluticasone-Salmeterol | Fluticasone Propion/Salmeterol | 26 | suppressed |
| Hydrocortisone | Hydrocortisone | 25 | suppressed |
| Methimazole | Methimazole | 25 | suppressed |
| Nexlizet | Bempedoic Acid/Ezetimibe | 25 | suppressed |
| Amitriptyline Hcl | Amitriptyline Hcl | 24 | suppressed |
| Cinacalcet Hcl | Cinacalcet Hcl | 24 | suppressed |
| Olanzapine | Olanzapine | 24 | suppressed |
| Ondansetron Hcl | Ondansetron Hcl | 24 | suppressed |
| Amiodarone Hcl | Amiodarone Hcl | 23 | suppressed |
| Megestrol Acetate | Megestrol Acetate | 23 | suppressed |
| Azelastine Hcl | Azelastine Hcl | 22 | suppressed |
| Clorazepate Dipotassium | Clorazepate Dipotassium | 22 | suppressed |
| Prasugrel Hcl | Prasugrel Hcl | 22 | suppressed |
| Propafenone Hcl | Propafenone Hcl | 22 | suppressed |
| Timolol Maleate | Timolol Maleate | 22 | suppressed |
| Butalbital-Acetaminophen-Caffe | Butalb/Acetaminophen/Caffeine | 21 | suppressed |
| Calcitonin-Salmon | Calcitonin,salmon,synthetic | 21 | suppressed |
| Clonidine | Clonidine | 21 | suppressed |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 21 | suppressed |
| Nexletol | Bempedoic Acid | 21 | suppressed |
| Sotalol | Sotalol Hcl | 21 | suppressed |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 21 | suppressed |
| Basaglar Kwikpen U-100 | Insulin Glargine,hum.Rec.Anlog | 20 | suppressed |
| Temazepam | Temazepam | 20 | suppressed |
| Metronidazole | Metronidazole | 19 | 16 |
| Novolog Flexpen | Insulin Aspart | 19 | suppressed |
| Rybelsus | Semaglutide | 19 | suppressed |
| Bisoprolol Fumarate | Bisoprolol Fumarate | 18 | suppressed |
| Metformin Hcl Er | Metformin Hcl | 18 | suppressed |
| Methotrexate | Methotrexate Sodium | 18 | suppressed |
| Mometasone Furoate | Mometasone Furoate | 18 | suppressed |
| Praluent Pen | Alirocumab | 18 | suppressed |
| Carbidopa-Levodopa | Carbidopa/Levodopa | 17 | suppressed |
| Methocarbamol | Methocarbamol | 17 | suppressed |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 16 | 12 |
| Cefadroxil | Cefadroxil | 16 | 11 |
| Desvenlafaxine Succinate Er | Desvenlafaxine Succinate | 16 | suppressed |
| Insulin Syringe | Syringe And Needle,insulin,1ml | 16 | suppressed |
| Lovastatin | Lovastatin | 16 | suppressed |
| Tramadol Hcl-Acetaminophen | Tramadol Hcl/Acetaminophen | 16 | suppressed |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 16 | suppressed |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 16 | suppressed |
| Fenofibrate | Fenofibrate | 15 | suppressed |
| Finasteride | Finasteride | 15 | suppressed |
| Phenobarbital | Phenobarbital | 15 | suppressed |
| Aripiprazole | Aripiprazole | 14 | suppressed |
| Clotrimazole-Betamethasone | Clotrimazole/Betamethasone Dip | 14 | suppressed |
| Labetalol Hcl | Labetalol Hcl | 14 | suppressed |
| Lantus | Insulin Glargine,hum.Rec.Anlog | 14 | suppressed |
| Budesonide | Budesonide | 13 | suppressed |
| Colchicine | Colchicine | 13 | suppressed |
| Colesevelam Hcl | Colesevelam Hcl | 13 | suppressed |
| Doxazosin Mesylate | Doxazosin Mesylate | 13 | suppressed |
| Halobetasol Propionate | Halobetasol Propionate | 13 | suppressed |
| Ipratropium Bromide | Ipratropium Bromide | 13 | suppressed |
| Novolin N | Insulin Nph Human Isophane | 13 | suppressed |
| Novolog | Insulin Aspart | 13 | suppressed |
| Tacrolimus | Tacrolimus | 13 | suppressed |
| Trulance | Plecanatide | 13 | suppressed |
| Ursodiol | Ursodiol | 13 | suppressed |
| Cartia Xt | Diltiazem Hcl | 12 | suppressed |
| Cefuroxime | Cefuroxime Axetil | 12 | suppressed |
| Chlordiazepoxide Hcl | Chlordiazepoxide Hcl | 12 | suppressed |
| Combivent Respimat | Ipratropium/Albuterol Sulfate | 12 | suppressed |
| Dilt-Xr | Diltiazem Hcl | 12 | suppressed |
| Divalproex Sodium Er | Divalproex Sodium | 12 | suppressed |
| Erythromycin | Erythromycin Base | 12 | suppressed |
| Fesoterodine Fumarate Er | Fesoterodine Fumarate | 12 | suppressed |
| Fosinopril Sodium | Fosinopril Sodium | 12 | suppressed |
| Haloperidol | Haloperidol | 12 | suppressed |
| Humulin R | Insulin Regular, Human | 12 | suppressed |
| Imipramine Hcl | Imipramine Hcl | 12 | suppressed |
| Lacosamide | Lacosamide | 12 | suppressed |
| Leflunomide | Leflunomide | 12 | suppressed |
| Phenytoin Sodium Extended | Phenytoin Sodium Extended | 12 | suppressed |
| Ranolazine Er | Ranolazine | 12 | suppressed |
| Zenpep | Lipase/Protease/Amylase | 12 | suppressed |
| Ziprasidone Hcl | Ziprasidone Hcl | 12 | suppressed |
| Benazepril-Hydrochlorothiazide | Benazepril/Hydrochlorothiazide | 11 | suppressed |
| Cefdinir | Cefdinir | 11 | 11 |
| Dutasteride | Dutasteride | 11 | suppressed |
| Fentanyl | Fentanyl | 11 | suppressed |
| Ibu | Ibuprofen | 11 | suppressed |
| Nitrofurantoin Mono-Macro | Nitrofurantoin Monohyd/M-Cryst | 11 | suppressed |
| Oxcarbazepine | Oxcarbazepine | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $272.06 · 18 records | Amgen Inc. | CRYSVITA, EVENITY, FANAPT, FARXIGA, OTEZLA, PROLIA, RELISTOR, REPATHA, TRELEGY ELLIPTA, TRULANCE | 7 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Farxiga play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error